2023年4月4日

分享这篇文章分享这篇文章提供的新闻同行评议的杂志,疼痛和治疗发表一项新的研究集中在评估的有效性BioWave®非侵入性周围神经刺激治疗慢性疼痛。使用后的46%减少疼痛BioWave两周。证实了一项新的研究发表在疼痛和治疗。87.6%的患者报告的改善使用BioWave两周后的生活质量。证实了一项新的研究发表在疼痛和治疗。42%的患者报告药物的使用是减少或消除在使用BioWave两周。证实了一项新的研究发表在疼痛和治疗。3.47分——平均减少疼痛评分(清廉规模)使用BioWave后两周。它证实了一项新的研究发表在疼痛和治疗。一项新的研究证实的疗效BioWave pain-blocking技术治疗慢性疼痛和改善生活质量。本文证实了小之前的研究的好处BioWave®技术治疗慢性疼痛。病人的人口规模(1511名患者)是在有史以来最大的人口规模进行非侵入性周围神经刺激。这项研究观察了使用BioWaveHOME®设备在慢性疼痛治疗。 Patients experienced significant reduction in overall pain and medication needs in just two weeks of starting to use BioWave®. BioWave® is a patented smarter pain blocking technology that provides immediate, deep, long-lasting relief of severe pain. BioWave devices deliver therapeutic electrical signals through skin directly to pain nerves in deep tissue to prevent pain from reaching the brain relieving chronic, acute or post-operative pain. BioWave technology provides 8 hours of pain relief on average following a 30-minute treatment*. It is easy to use at home or on the go. The five main outcomes the study found were: overall pain reduction after using BioWave for two weeks was 46%. The average reduction in pain score was 3.47 points (0-10 scale), which is a significant reduction. An improvement in quality of life was reported in 87.6% of patients; 42% of patients reported they were able to eliminate or reduce their medication. Over 97% of patients wanted to continue the BioWave therapy. Most importantly the effect on functional lifestyle (mood, sleep, standing, sitting, etc.) was improved across the board. There were no adverse reactions or complications reported in the 1511 patient outcomes. "Although survey studies have inherent limitations such as duration and compliance biases with such an overwhelming benefit in every category, we believe that noninvasive neuromodulation therapy is a promising, safe, and cost-effective therapy," wrote the authors. "The recent study confirms the efficacy of our patented high frequency pain blocking technology for the treatment of severe chronic pain, and for improvement in function and qualities of life for patients," said Brad Siff, Founder & President of BioWave Corporation. "Our mission is to help people win their battle with severe pain so they can get back to their daily activities. BioWave is changing lives every day and it's extremely rewarding to be able to help these patients who suffer from pain. The published clinical paper demonstrates our dedication to providing proven, innovative efficacy for our customers," said Brad Siff. About BioWave Corp. BioWave is committed to delivering immediate, deep, and long-lasting relief of severe pain by offering innovative solutions to treat pain using the company's patented, high-frequency peripheral nerve stimulation technology . Products include BioWavePENS® , BioWavePRO® , BioWaveHOME® , BioWaveGO® RX, a portable unit, BioWaveGO an over-the-counter device, and BioWraps® , wearable compression electrode garments. BioWave® started in professional sports – the NY Football Giants were the company's first customer. Today BioWave has been used by over 140 NCAA teams and well over 100 PRO teams in the NFL, MLB, NBA, NHL, and MLS. BioWave technology and solutions are also widely used by many VA hospitals, active military bases, pain, and ortho clinics. BioWave devices are FDA-cleared, and clinically proven to deliver safe and effective treatment of pain without the need for prescription drugs. BioWave is available under Federal Supply Schedule contract number V797D-70205. More information about the company's products and solutions can be found at BioWave.com . Contacts